How Ebola Kills: Pathophysiology, Cytokine Storm, and Organ Failure

Introduction: A Virus That Overwhelms Every Defence

Ebola virus disease is one of the deadliest infections known to medicine. Without treatment, case fatality rates range from 25% to 90% depending on the species and outbreak context. But what exactly happens inside the human body that causes this catastrophic outcome? Understanding the pathophysiology of Ebola helps explain why it is so deadly — and why the treatments that do work, work.

Step 1: Viral Entry — Targeting the Body’s Defenders

Unlike many viruses, Ebola has a remarkably broad cell tropism — it can infect almost every cell type in the body. But it begins by targeting the very cells meant to defend against it.

Primary target cells:

Monocytes and macrophages: the front-line soldiers of the innate immune system
Dendritic cells: the critical coordinators of adaptive immunity

The Ebola glycoprotein (GP) on the viral surface binds to multiple attachment factors on the cell surface (including DC-SIGN, TIM-1, and NPC1 — the intracellular receptor required for membrane fusion). By infecting macrophages first, the virus exploits these cells as both a replication factory and a transport vehicle, spreading throughout the body via the lymphatic and circulatory systems.

Step 2: Immune Evasion — Disabling the Alarm System

Ebola has evolved extraordinarily effective mechanisms to suppress the immune response:

VP35 Blocks Interferon

The viral protein VP35 actively inhibits the production of type I interferons (IFN-α and IFN-β) — the body’s primary antiviral alarm signals. By blocking interferon signalling, Ebola prevents neighbouring uninfected cells from entering an antiviral state.

VP24 Blocks STAT1 Nuclear Translocation

Even when interferon is produced, VP24 prevents the signal from reaching the nucleus by blocking STAT1 transport. The downstream genes that would activate cellular antiviral programs cannot be switched on.

GP-Mediated Dendritic Cell Dysfunction

Ebola infection of dendritic cells renders them functionally impaired — they cannot efficiently activate T lymphocytes. This delays and disrupts the adaptive immune response, giving the virus days of largely unimpeded replication.

The result: the virus replicates to extremely high titres (up to 10^9 viral particles per millilitre of blood in fatal cases) before the adaptive immune system can mount an effective response.

Step 3: Cytokine Storm — The Immune Overreaction

Once macrophages are massively infected, they begin releasing enormous quantities of inflammatory cytokines and chemokines, including:

TNF-α (tumour necrosis factor alpha)
IL-6 (interleukin-6)
IL-1β (interleukin-1 beta)
MCP-1 (monocyte chemoattractant protein-1)
IL-8
MIP-1α and MIP-1β

This cytokine storm is a dysregulated inflammatory response in which the immune system’s attempt to fight the virus causes massive collateral damage to the host.

The cytokine storm drives:

Systemic vasodilation and fluid redistribution
Increased vascular permeability
Activation of the coagulation cascade
Direct tissue damage

Step 4: Vascular Damage and Coagulopathy

One of the most distinctive features of Ebola is its effect on blood vessels and clotting:

Endothelial Injury

Ebola infects vascular endothelial cells, the cells lining blood vessel walls. The combination of direct viral infection and cytokine-mediated inflammation causes:

Increased vascular permeability → fluid leaks from blood vessels into tissues
Endothelial activation → pro-coagulant surface
Loss of vascular tone → hypotension

Disseminated Intravascular Coagulation (DIC)

The extreme cytokine environment and viral proteins activate the coagulation cascade simultaneously throughout the body — causing DIC, a paradoxical condition where:

Widespread small clots form in blood vessels (thrombosis), consuming clotting factors
As clotting factors are depleted, the blood loses the ability to clot
Both bleeding and clotting occur simultaneously

This explains the hemorrhagic manifestations of Ebola: bleeding from IV sites, mucous membranes, the gastrointestinal tract, and (in late-stage severe cases) from multiple body orifices. It is important to note that hemorrhage is actually a late manifestation seen in only about 20–50% of cases — not the primary cause of death in most patients.

Step 5: Multi-Organ Failure

As the infection progresses, multiple organ systems fail:

Liver Failure

Ebola infects hepatocytes (liver cells), causing necrosis. The liver is a major site of viral replication. Liver failure results in:

Loss of coagulation factor synthesis (worsening DIC)
Elevated liver enzymes (AST, ALT)
Hypoglycaemia (the liver cannot maintain blood glucose)
Jaundice in some cases

Renal Failure

Combination of hypotension (reduced blood flow to kidneys), direct viral infection of renal cells, and inflammatory cytokines causes acute kidney injury. Oliguria (reduced urine output) is a poor prognostic sign.

Adrenal Failure

Ebola frequently infects the adrenal glands, causing cortical necrosis. Adrenal insufficiency contributes to refractory hypotension (shock that doesn’t respond to fluid resuscitation).

Neurological Involvement

Encephalopathy (altered consciousness, confusion, seizures) is seen in some patients, particularly late in the disease course. Whether this reflects direct viral neuroinvasion, metabolic encephalopathy (from liver/kidney failure), or cytokine-mediated neuroinflammation is still debated.

The Actual Cause of Death

Most patients who die from EVD die from hypovolemic shock (loss of circulating blood volume due to severe diarrhoea and vomiting), compounded by:

DIC-related bleeding
Multi-organ failure (liver, kidney, adrenal)
Septic-like physiology from cytokine storm

Contrary to popular imagery, death from dramatic hemorrhage (bleeding to death) is not the most common outcome — it occurs in a minority of fatal cases. The more common picture is a patient succumbing to dehydration, electrolyte imbalances, organ failure, and shock.

Why Some People Survive

Survivors mount a qualitatively different immune response:

Earlier antibody production: IgM and IgG against Ebola GP appear in the first 1–2 weeks
Effective T-cell responses: CD8+ cytotoxic T cells clear infected cells
Controlled cytokine response: survivors show lower levels of the most damaging cytokines
Preserved innate sensing: early interferon signalling may be better preserved

Studies from the 2014 West Africa epidemic showed that survivors had detectable immune responses before peak viral load, while fatal cases had high viral loads but minimal detectable immune response until too late.

Implications for Treatment

Understanding this pathophysiology explains why the approved treatments work:

Inmazeb and Ebanga (monoclonal antibodies): prevent the virus from entering and infecting new cells by blocking the GP — ideally before viral load becomes uncontrollably high
IV fluid resuscitation: directly combats the hypovolemia driving shock
Electrolyte replacement: corrects the sodium, potassium, and glucose abnormalities driven by GI losses and liver dysfunction
Early treatment: the earlier antibody therapy is given (when viral load is still low), the better the survival outcome — consistent with the model that once the cytokine storm is fully established, even targeted antivirals have limited effect